CHICAGO–A next-generation immunotherapy in development by Bristol-Myers Squibb Co. may reinvigorate immune system activity against cancer cells with fewer side effects and greater antitumor activity than the company’s breakthrough melanoma drug Yervoy (ipilimumab).
In a Phase I trial that enrolled 296 patients with five kinds of tumors, all of them advanced, BMS-936558 elicited...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?